ASTRAZENECA PLC

Overview

AstraZeneca plc is a global biopharmaceutical company that researches, develops and commercialises prescription medicines. Its principal areas are oncology, biopharmaceuticals—including cardiovascular, renal and metabolism, and respiratory and immunology medicines—and rare diseases. The company states its purpose as “pushing the boundaries of science to deliver life-changing medicines.” [1]+2

Headquartered in Cambridge, UK, AstraZeneca has an active presence in more than 80 countries. It reported $58.7 billion in total revenue and approximately 95,100 employees in continuing operations in 2025. The company was formed in 1999 through the merger of Sweden’s Astra AB and the UK’s Zeneca Group.[4][5] [6]+7

Products & services

AstraZeneca’s oncology medicines include Tagrisso (osimertinib), an EGFR inhibitor for certain forms of non-small-cell lung cancer; Imfinzi (durvalumab), an antibody used in several cancers; Lynparza (olaparib), a PARP inhibitor; and Calquence (acalabrutinib), a BTK inhibitor for certain blood cancers. Its portfolio also includes Enhertu, a HER2-directed antibody-drug conjugate, and Truqap, used in combination therapy for certain breast cancers. Oncology accounted for approximately 43% of AstraZeneca’s product sales in 2025.[9][10]

In cardiovascular, renal and metabolic medicine, Farxiga/Forxiga (dapagliflozin) is an SGLT2 inhibitor used for type 2 diabetes, heart failure and chronic kidney disease, while Lokelma treats elevated blood potassium. Respiratory products include Symbicort, an inhaled corticosteroid and bronchodilator combination; Breztri, a three-component inhaled COPD treatment; and biologics Fasenra and Tezspire for severe asthma. The vaccines and immune therapies portfolio includes FluMist influenza vaccine and Beyfortus, a long-acting antibody used to help prevent respiratory syncytial virus disease in infants.[11][12]

Rare-disease medicines include Ultomiris and Soliris, which inhibit complement protein C5, and Strensiq, an enzyme replacement therapy for hypophosphatasia. Alongside its medicines, AstraZeneca offers medical information for healthcare professionals and patient affordability assistance in the United States, including co-pay support and its AZ&Me patient assistance programme.[13]+2 [9]+6

Geographic presence

AstraZeneca is headquartered in Cambridge, UK, and has operations across more than 80 countries. In 2025, the US accounted for $23.4 billion, or about 42% of product sales; Emerging Markets accounted for $15.1 billion (27%), Europe for $12.0 billion (22%), and Rest of World for $5.1 billion (9%). China is included within Emerging Markets.[4][16]

On a separate total-revenue basis, sales attributed to legal entities in the US were $24.0 billion in 2025, compared with $6.6 billion in China and $4.4 billion in the UK. These country figures reflect the location of the selling legal entity and should not be read as a breakdown of the regional product-sales figures.[17][18]

AstraZeneca’s 2025 average workforce was 95,100: 10,600 in the UK, 26,900 in the rest of Europe, 25,200 in the Americas, and 32,400 across Asia, Africa and Australasia. Its research and manufacturing footprint includes sites in Cambridge, UK; Gaithersburg, Maryland; and Gothenburg and Södertälje, Sweden.[19]+3 [16]+7

Business segments

AstraZeneca reports **one operating and reportable segment**: its integrated pharmaceutical business. It also presents product sales by therapeutic area, but these areas are not separate financial-reporting segments.[23][24]

Based on 2025 product sales, **Oncology** contributed approximately 43%, covering cancer treatments including Tagrisso, Imfinzi and Enhertu. **Cardiovascular, Renal & Metabolism (CVRM)** contributed about 23%, with medicines addressing conditions such as diabetes, heart failure and chronic kidney disease. **Respiratory & Immunology** accounted for about 15%, including asthma and chronic obstructive pulmonary disease treatments.[3]+3

**Rare Disease** contributed approximately 16%, with a focus that includes complement-mediated disorders and products such as Ultomiris and Soliris. **Vaccines & Immune Therapies** contributed about 2%, focusing on infectious-disease prevention and immune therapies, including products for respiratory syncytial virus. **Other Medicines** accounted for the remaining roughly 2%. These percentages use product sales as the denominator; they do not allocate alliance and collaboration revenue across therapeutic areas.[3]+2 [23]+7

Company history

AstraZeneca’s origins lie in Sweden’s Astra, whose history dates to 1913, and the UK’s Zeneca, formed in 1993 when Imperial Chemical Industries separated its pharmaceutical businesses. Astra AB and Zeneca Group PLC merged in 1999 to form AstraZeneca.[5]

The company expanded its biologics business through the acquisition of MedImmune in 2007.[30] Pascal Soriot became chief executive in 2012, and in 2013 AstraZeneca selected Cambridge, UK, as a strategic research and development centre.[31][32] In 2020, it partnered with the University of Oxford to develop and distribute a COVID-19 vaccine; in 2021, it completed the acquisition of Alexion Pharmaceuticals, expanding into rare diseases.[33][34] [5]+5

Sources

• careers.astrazeneca.com[1]
• www.astrazeneca.com[2]
• www.sec.gov[3]
• www.sec.gov[4]
• www.astrazeneca.com[5]
• ASTRAZENECA PLC — Full financial report (2025 Y)
  10 citations

  [6][7][8][9][10][12][16][17][18][19]
• ASTRAZENECA PLC — Full financial report (2024 Y)
  3 citations

  [11][13][23]
• www.astrazeneca.com[14]
• www.astrazeneca.com[15]
• www.astrazeneca.com[20]
• www.astrazeneca.com[21]
• www.astrazeneca.com[22]
• ASTRAZENECA — Full financial report (2025 Y)
  6 citations

  [24][25][26][27][28][29]
• www.sec.gov[30]
• www.astrazeneca.com[31]
• www.astrazeneca.com[32]
• www.ox.ac.uk[33]
• www.astrazeneca.com[34]